Torrent Pharmaceuticals announced that the merger of Mumbai-based JB Chemicals & Pharmaceuticals with the company has entered its final phase, with the transaction expected to become effective within the next one to two months. Aman Mehta, Managing Director of Torrent Pharmaceuticals and a Board member of JB Chemicals, said the merger process is progressing as planned and has already secured the required shareholder approvals. “On the merger process we have received the requisite shareholder approval for merger of JB Pharma with Torrent and we are in the last stage of the process,” Mehta said. He added that the hearing date is scheduled for the second week of June, after which the merger is expected to become effective within one to two months.
Shareholder and regulatory approvals already secured
The merger scheme received approvals from shareholders of both companies in April 2026. In addition, the companies secured approvals from public shareholders and received no-objection letters from stock exchanges. Under the approved share exchange ratio, shareholders of JB Chemicals, excluding Torrent Pharmaceuticals, will receive 51 equity shares of Torrent Pharma for every 100 shares held in JB Chemicals. The appointed date for the merger has been fixed as January 21, 2026.
Torrent Pharma already overseeing integration
Torrent Pharma has already been exercising operational control over JB Chemicals for the past four months as part of the ongoing integration process. According to Mehta, JB Chemicals’ strong domestic brands continue to provide confidence for future growth opportunities within the merged entity. “The brands in the India business in particular continue to give us confidence. These are such widely established and recognized brands and familiarity is so high that in a merged entity it could certainly be possible to grow further,” he said.
India business to drive future growth
The merged entity plans to sharpen its focus on the Indian pharmaceutical market, which Torrent Pharma views as its primary long-term growth engine. “The objective that we have taken is to change the mix profile and growth profile of the company as JB which would be more geared to India growth as an outperformance driver rather than a mix of international and India,” Mehta stated. While international operations will continue to remain important, the company expects future growth momentum to come mainly from recovery in the domestic branded formulations business and revenue synergies arising from the merger integration.
Field force rationalisation likely during integration
Torrent Pharma also indicated that some rationalisation within the field force could take place as the integration process advances. As reported by thehindubusinessline.com, currently, the company’s integration efforts are focused on aligning business practices, operating structures, and sales processes across the combined organisation to ensure a smoother transition and stronger operational efficiency.
